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STATE-OF-THE-ART PAPERS STATE-OF-THE-ART PAPERSTranscatheter Aortic Valve Replacement and MR 2643
Luis Nombela-Franco, Henrique Barbosa Ribeiro, Marina Urena, Ricardo Allende, Ignacio Amat-Santos,
Robert DeLarochellière, Eric Dumont, Daniel Doyle, Hugo DeLarochellière, Jerôme Laﬂamme,
Louis Laﬂamme, Eulogio García, Carlos Macaya, Pilar Jiménez-Quevedo, Mélanie Côté,
Sebastien Bergeron, Jonathan Beaudoin, Philippe Pibarot, Josep Rodés-Cabau
Signiﬁcant mitral regurgitation (MR) is frequent in patients with severe aortic stenosis.
The purpose of this review is to present the current knowledge on the clinical impact and
post-procedural evaluation of concomitant signiﬁcant MR in patients with severe aortic
stenosis undergoing surgical or transcatheter aortic valve replacement.STATE-OF-THE-ART PAPERSTreatment of In-Stent Restenosis 2659
Fernando Alfonso, Robert A. Byrne, Fernando Rivero, Adnan Kastrati
In-stent restenosis (ISR) mainly results from aggressive neointimal proliferation, but recent
data also suggest that neoatherosclerosis may play an important role. In this review, the
authors discuss the pathogenesis and the currently-available therapeutic strategies for the
management of ISR.(continued on page A-31)
JUNE 24, 2014 (continued) A-31VIEWPOINT VIEWPOINTAnalysis of the 2013 Cholesterol Guideline 2674
Seth S. Martin, Thura T. Abd, Steven R. Jones, Erin D. Michos, Roger S. Blumenthal, Michael J. Blaha
In this paper, the authors discuss what they believe are the strengths and shortcomings of the
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce
Atherosclerotic Cardiovascular Risk in Adults. They agree with the current guideline, which
prioritizes statin therapy, expands the focus to include atherosclerotic cardiovascular disease
including stroke, and uses cardiovascular risk to determine statin eligibility. They, however,
feel that there is still a role for using lipid goals and that the guideline should provide
guidance on cholesterol evaluation and broaden the concept of age underpinning risk-based
decisions.CLINICAL RESEARCH CARDIOMETABOLIC RISKObesity and Subclinical Atherosclerosis 2679
Yoosoo Chang, Bo-Kyoung Kim, Kyung Eun Yun, Juhee Cho, Yiyi Zhang, Sanjay Rampal, Di Zhao,
Hyun-Suk Jung, Yuni Choi, Jiin Ahn, João A. C. Lima, Hocheol Shin, Eliseo Guallar, Seungho Ryu
The authors compared the coronary artery calcium (CAC) scores of metabolically-healthy
obese (MHO) and metabolically-healthy normal-weight individuals. A cohort of 14,828
metabolically-healthy men and women who had no known cardiac disease, no metabolic
syndrome component, and a homeostasis model assessment of insulin resistance
(HOMA-IR) <2.5 were evaluated. MHO individuals had a higher prevalence of coronary
calciﬁcation. In multivariable-adjusted models, the CAC score ratio comparing MHO to
normal-weight participants was 2.26. After further adjustments for metabolic risks
(mediation analysis), this association was no longer statistically signiﬁcant. The study
concludes that MHO participants had a higher prevalence of subclinical coronary
atherosclerosis compared with metabolically healthy normal-weight participants. This
association, however, was mediated by metabolic risk factors at levels below those considered
abnormal.
Editorial Comment: Rishi Puri, p. 2687(continued on page A-32)
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Morten Lamberts, Gregory Y. H. Lip, Martin H. Ruwald, Morten Lock Hansen, Cengiz Özcan,
Søren L. Kristensen, Lars Køber, Christian Torp-Pedersen, Gunnar H. Gislason
Lamberts and colleagues investigate the impact of atrial ﬁbrillation (AF) and antithrombotic
treatment on prognosis in patients with heart failure (HF) and coexisting vascular disease.
A total of 37,464 patients were included (mean age 74.5 years, 36.3% females) with a mean
follow-up of 3 years, during which 20.7% of patients were categorized as having prevalent AF
and 17.2% as having incident AF. In prevalent and incident AF patients, as compared with
vitamin K antagonist (VKA) therapy alone, VKA plus antiplatelet agent was not associated
with a decreased risk of thromboembolism or myocardial infarction. Bleeding risks were
signiﬁcantly increased with combination therapy in both groups (hazard ratios: 1.31 and 2.71,
respectively). The authors conclude that in AF patients with coexisting HF and vascular
disease, adding single antiplatelet therapy to VKA therapy is not associated with additional
beneﬁt to thromboembolic or coronary risk, but it notably increased bleeding risk.
Editorial Comment: Srijita Sen-Chowdhry, Richard J. Gordon, p. 2699HEART RHYTHM DISORDERSCircadian Variation in the SCD-HeFT Study 2702
Kristen K. Patton, Anne S. Hellkamp, Kerry L. Lee, Daniel B. Mark, George W. Johnson, Jill Anderson,
Gust H. Bardy, Jeanne E. Poole, for the SCD-HeFT Investigators
The authors sought to determine whether circadian patterns in ventricular arrhythmias (VAs)
occur in a primary prevention implantable cardioverter-deﬁbrillator (ICD) population. Of
811 ICD patients, 186 subjects received 714 ICD therapy episodes for life-threatening VAs.
There was no morning (6 AM to 12 PM) peak; however, a typical early morning (12 AM to
6 AM) nadir was seen in the overall cohort. A signiﬁcant Monday morning peak in therapies
occurred only in patients not on beta-blockers (22% of events for the week). In the SCD-
HeFT (Sudden Cardiac Death in Heart Failure Trial) population, the distribution of life-
threatening VAs failed to demonstrate a typical early morning peak or increased VA events
on Mondays.
Editorial Comment: Kelley P. Anderson, p. 2709(continued on page A-33)
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David E. Krummen, Justin Hayase, David J. Morris, Jeffrey Ho, Miriam R. Smetak, Paul Clopton,
Wouter-Jan Rappel, Sanjiv M. Narayan
Krummen and colleagues mapped human ventricular ﬁbrillation (VF) to deﬁne mechanistic
differences between episodes requiring deﬁbrillation versus those that spontaneously
terminate. A total of 26 patients undergoing ablation for ventricular arrhythmias underwent
VF mapping. Rotators were present in 16 of 19 patients with VF and in all patients with
sustained VF. Sustained, but not self-limiting, VF was characterized by greater rotor stability.
Additionally, biventricular rotor locations in sustained VF were conserved across multiple
inductions (7 of 7 patients). In patients with and without structural heart disease, the
formation of stable rotors identiﬁes individuals whose VF requires deﬁbrillation from those in
whom VF spontaneously self-terminates.TRANSLATIONAL RESEARCHOmentin and Myocardial Ischemic Injury 2722
Yoshiyuki Kataoka, Rei Shibata, Koji Ohashi, Takahiro Kambara, Takashi Enomoto, Yusuke Uemura,
Yasuhiro Ogura, Daisuke Yuasa, Kazuhiro Matsuo, Takanobu Nagata, Toyoharu Oba, Hideo Yasukawa,
Yasushi Numaguchi, Takahito Sone, Toyoaki Murohara, Noriyuki Ouchi
This study evaluates the impact of omentin on myocardial injury in patients after acute
myocardial infarction (AMI) and in a mouse model of ischemia/reperfusion (I/R). High
levels of plasma omentin were associated with improvement of heart damage and function
after reperfusion therapy in patients with AMI. Systemic administration of human omentin
to mice led to a reduction of myocardial infarct size and apoptosis following I/R accompanied
by enhanced phosphorylation of AMP-activated protein kinase (AMPK) and Akt in the
ischemic heart. This study shows that omentin functions as an adipokine that ameliorates
acute ischemic injury in the heart by suppressing myocyte apoptosis through both
AMPK- and Akt-dependent mechanisms.(continued on page A-34)
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Colin E. Murdoch, Sanjay Chaubey, Lingfang Zeng, Bin Yu, Aleksander Ivetic, Simon J. Walker,
Davy Vanhoutte, Stephane Heymans, David J. Grieve, Alison C. Cave, Alison C. Brewer, Min Zhang,
Ajay M. Shah
The authors performed this study to evaluate the effect of endothelial dysfunction on the
development of cardiac hypertrophy and ﬁbrosis. Transgenic mice with endothelial-speciﬁc
NADPH oxidase-2 overexpression (TG) and wild-type littermates received long-term
angiotensin (AngII) infusion to induce hypertrophy and ﬁbrosis. TG mice had similar
systolic hypertension and hypertrophy to wild-type mice but developed greater cardiac ﬁbrosis
and isolated left ventricular diastolic dysfunction. Exposure to AngII also promoted
myocardial inﬂammatory cell inﬁltration and enhanced endothelial–mesenchymal transition.
This may be an important mechanism underlying cardiac ﬁbrosis and diastolic dysfunction
during increased renin-angiotensin activation.
Editorial Comment: Robert J. Bache, Yingjie Chen, p. 2742
